Added to YB: 2026-05-18
Pitch date: 2026-05-15
NRXS [neutral]
NeurAxis, Inc.
-7.05%
current return
Author Info
MVC Investing is a long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation. Sign up for the newsletter.
Company Info
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Market Cap
$95.1M
Pitch Price
$7.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.66
P/E
-10.13
EV/Sales
20.65
Sector
Health Care Equipment and Supplies
Category
growth
NeurAxis (NRXS): Q1 2026 Earnings Review
NRXS (earnings): Q1 rev $1.6M (+80% YoY), best quarter ever. ASP +33% to $1,017 on payer mix shift. Gross margin 86.4% (+200bps). Op loss $1.7M (-24% YoY), cash burn $1.2M. Prior auth approval 32% vs 12% (target 80%). 66 ordering accounts (+18%), $24k rev/account (+53%). At 32% approval, latent demand = $18.3M annualized; 80% target = $14.6M vs $6.4M run rate. 101M covered lives, Medicaid adding 20-30% reimbursable mix. Breakeven ~$15M annual rev (vs $6.4M current). VA activation ahead of schedule. Mgmt confident on major payer progress but no timeline. Risks: payer timing, adoption pace.
Read full article (9 min)